Lung Cancer
Combating malnutrition should be at the forefront of cancer care, as studies have shown that up to 80% of patients with cancer are malnourished at some point during their treatment. Dr. Spees describes a new clinical trial focused on improving the nutrition of patients with lung cancer. Read More ›
By Dana Taylor
Although most of the drugs being developed for lung cancer these days are for non–small-cell lung cancer (NSCLC), there may be a shift on the horizon as new treatment options emerge for patients with small-cell lung cancer. Read More ›
By Dana Taylor
It has become increasingly clear that lung cancer can be caused by different factors, including some environmental chemicals. Lung cancer in never smokers under the microscope. Read More ›
Christie Bevington shares her story of how immunotherapy was the only treatment that helped stop her cancer progression and relieve her back pain caused by lung cancer. Read More ›
By Dana Taylor
Two experts discuss the advances made in lung cancer with the introduction of new immunotherapies, which have extended life for patients, and why testing for biomarkers is crucial. Read More ›
In May 2021, the FDA approved Rybrevant (amivantamab-vmjw), an intravenous antibody that targets mutations in the EGFR and MET pathways, for the treatment of adults with non–small-cell lung cancer and EGFR exon 20 insertion mutations. This is the first drug approved for lung cancer with EGFR exon 20 insertion mutations. Read More ›
In May 2021, the FDA approved Lumakras (sotorasib), an oral KRAS inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer associated with KRAS G12C mutation. Lumakras is the first drug approved for any cancer associated with any KRAS mutation. Read More ›